Clinical Trial Update: A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating [225Ac]Ac-AKY-1189 for solid tumors is currently recruiting, including urothelial carcinoma of the bladder and triple-negative breast c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Adenocarcinoma
• Colorectal Adenocarcinoma
• Head and Neck Cancer
• Hormone Receptor-positive Breast Cancer
• Non-small Cell Lung Cancer
• Triple-negative Breast Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• AKY-1189 (AKY-1189)

Snippet

Sponsor: Aktis Oncology, Inc. | Conditions: Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC) | Phase 1 | Status: RECRUITING